PMID- 21094842
OWN - NLM
STAT- MEDLINE
DCOM- 20110307
LR  - 20181201
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 42
IP  - 9
DP  - 2010 Nov
TI  - Serum midkine is related to NYHA class and cystatin C in heart transplant 
      recipients.
PG  - 3704-7
LID - 10.1016/j.transproceed.2010.08.026 [doi]
AB  - Heart transplantation is now the established method of therapy for end-stage 
      heart failure, with significantly improved outcomes over recent years. However, 
      an increasingly prevalent complication in this population is that chronic kidney 
      disease appears to be generally associated with subclinical inflammation. Midkine 
      is a heparin-binding growth factor with various functions ranging from cell 
      growth and survival to angiogenesis, repair, and inflammation. Recently, serum 
      midkine has been reported to be a novel marker of cardiac events in heart failure 
      patients. The aim of this study was to assess midkine concentration in 134 heart 
      transplant recipients in relation to kidney function and New York Heart 
      Association (NYHA) class. Heart transplant recipients had significantly higher 
      serum creatinine, urea, cholesterol, triglycerides, fasting glucose, white blood 
      cell count, and serum midkine, and lower estimated glomerular filtration rate 
      than the control group. Serum midkine levels rose together with advancing NYHA 
      class. Serum midkine was related to kidney function, NT-proBNP, transferrin, and 
      prednisone dose. Cystatin C and NT-proBNP class turn out to be predictors of 
      midkine in heart transplant recipients. Midkine levels are dependent on heart and 
      kidney function, and might also represent a surrogate marker of subclinical 
      inflammation.
CI  - Copyright (c) 2010 Elsevier Inc. All rights reserved.
FAU - Przybylowski, P
AU  - Przybylowski P
AD  - Department of Cardiovascular Surgery and Transplantology, Jagiellonian 
      University, John Paul II Hospital, Krakow, Poland. plotrus@aol.com
FAU - Malyszko, J
AU  - Malyszko J
FAU - Malyszko, J S
AU  - Malyszko JS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Biomarkers)
RN  - 0 (CST3 protein, human)
RN  - 0 (Cystatin C)
RN  - 0 (Cytokines)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 137497-38-2 (Midkine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Cystatin C/*blood
MH  - Cytokines/*blood
MH  - Glomerular Filtration Rate
MH  - Heart/physiopathology
MH  - *Heart Transplantation/adverse effects
MH  - Humans
MH  - Kidney/physiopathology
MH  - Middle Aged
MH  - Midkine
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Poland
MH  - Regression Analysis
MH  - Stroke Volume
MH  - Treatment Outcome
EDAT- 2010/11/26 06:00
MHDA- 2011/03/08 06:00
CRDT- 2010/11/25 06:00
PHST- 2010/07/19 00:00 [received]
PHST- 2010/08/11 00:00 [accepted]
PHST- 2010/11/25 06:00 [entrez]
PHST- 2010/11/26 06:00 [pubmed]
PHST- 2011/03/08 06:00 [medline]
AID - S0041-1345(10)01237-6 [pii]
AID - 10.1016/j.transproceed.2010.08.026 [doi]
PST - ppublish
SO  - Transplant Proc. 2010 Nov;42(9):3704-7. doi: 10.1016/j.transproceed.2010.08.026.